Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYK vs MDT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
MDT Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)
MDT Overall Winner
6-Pillar Tally: SYK 3 – 3 MDT
Matrix Metrics: SYK 3 – 6 MDT
As of Nov 16, 2026, Medtronic plc (MDT) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas MDT carries 45.8/100 (HOLD) at $103.38 (17.0x Forward P/E, 20.1% operating margin).
- Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. MDT 45.8/100 HOLD), MDT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (20.1% vs. 24.0% operating margin) and revenue trajectory (+13.7% vs. +7.6% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SYK vs MDT
SYK
Stryker Corporation
$310.79
+0.37% 1D
Market Cap
$118.9B
TTM Revenue
$26.3B
Forward P/E
19.0x
Beta / 30D Vol
0.22β · 50% Vol
Unified Composite Score
46.5
HOLD
Tech 37.0
Fund 49.0
Flow 58.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
MDT
Head-to-Head Winner
Medtronic plc
$103.38
+0.5% 1D
Market Cap
$129.2B
TTM Revenue
$37.5B
Forward P/E
17.0x
Beta / 30D Vol
0.15β · 33% Vol
Unified Composite Score
45.8
HOLD
Tech 22.0
Fund 46.0
Flow 69.0
Mom 46.5
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (SYK 3 – 3 MDT)
1. Valuation Multiples
MDT
Forward P/E
19.0x
17.0x
Trailing P/E
33.3x
24.8x
PEG Ratio
1.54x
1.83x
EV / Revenue
5.0x
4.1x
2. Growth & Scale
MDT
Revenue Growth (YoY)
+7.6%
+13.7%
Earnings Growth (YoY)
-11.7%
+40.7%
TTM Revenue (USD)
$26.3B
$37.5B
Market Cap
$118.9B
$129.2B
3. Profitability & Quality
SYK
Gross Margin
65.7%
65.3%
Operating Margin
24.0%
20.1%
Net Profit Margin
13.8%
13.9%
Return on Equity (ROE)
16.0%
10.7%
4. Balance Sheet & Cash Flow
SYK
Cash Generation (TTM)
$4.57B
$6.13B
Cash Flow Margin
17.4%
16.3%
Net Cash / Leverage
$11.7B Net Debt (0.64x D/E)
$26.5B Net Debt (0.56x D/E)
Dividend Yield
1.10%
2.80%
5. Options & Positioning
SYK
Options Structure Phase
SURGE
CONSOLIDATION
Current IV / %ile
28.1% (5th %ile)
30.6% (12th %ile)
Put/Call OI Skew
0.30x (Call-Skewed)
0.30x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
MDT
OpEx & R&D Intensity
41.7% of Rev ($11.0B)
45.2% of Rev ($17.0B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Concentrated Oligopoly Moat
Concentrated Oligopoly Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SYK (3) vs MDT (6)| Institutional Metric | SYK | MDT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $118.9B | $129.2B | MDT | |
| Trailing P/E Ratio | 33.3x | 24.8x | MDT | |
| Forward P/E Ratio | 19.0x | 17.0x | MDT | |
| Revenue Growth (YoY) | +7.6% | +13.7% | MDT | |
| Operating Margin (TTM) | 24.0% | 20.1% | SYK | |
| Net Profit Margin | 13.8% | 13.9% | Tie | |
| Return on Equity (ROE) | 16.0% | 10.7% | SYK | |
| 52-Week Range Position | 36% ($267–$389) | 91% ($73–$106) | MDT | |
| Beta / 30D Volatility | 0.22β · 50% Vol | 0.15β · 33% Vol | MDT | |
| Unified Institutional Score | 46.5 / 100 (HOLD) | 45.8 / 100 (HOLD) | SYK | |
| Trailing 12M Revenue (USD) | $26.3B | $37.5B | Scale | |
| Gross Profit Margin (TTM) | 65.7% | 65.3% | Quality | |
| PEG Ratio & EV / Revenue | 1.54x PEG · 5.0x EV/Rev | 1.83x PEG · 4.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $4.57B ($11.7B Net Debt (0.64x D/E)) | $6.13B ($26.5B Net Debt (0.56x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MDT +3.63 pp
3M Horizon
MDT +18.47 pp
6M Horizon
MDT +34.48 pp
1Y Horizon
MDT +24.3 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SYK Revenue | MDT Revenue | SYK Op. Margin | MDT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $14.9B | $30.6B | 18.2% | 20.5% | MDT |
| FY2020 | $14.3B | $28.9B | 15.5% | 16.6% | MDT |
| FY2021 | $17.1B | $30.1B | 15.1% | 14.9% | SYK |
| FY2022 | $18.4B | $31.7B | 15.4% | 18.2% | MDT |
| FY2023 | $20.5B | $31.2B | 19.0% | 17.6% | SYK |
| FY2024 | $22.6B | $32.4B | 16.3% | 15.9% | SYK |
| FY2025 | $25.1B | $33.5B | 19.5% | 17.8% | SYK |
| FY2026 | N/A | $36.4B | N/A | 17.8% | MDT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SYK
SURGE
Current IV
28.1%
IV Percentile
5th %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MDT
CONSOLIDATION
Current IV
30.6%
IV Percentile
12th %ile
Put/Call OI Skew
0.30x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact MDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SYK Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
OpEx & R&D Reinvestment
41.7% of Rev ($11.0B)
90D Engineering Disclosures
0 Published · Surgical Robotics
MDT Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
OpEx & R&D Reinvestment
45.2% of Rev ($17.0B)
90D Engineering Disclosures
0 Published · Surgical Robotics
Investor FAQ SYK vs MDT Key Questions & Quantitative Answers
As of Nov 16, 2026, Medtronic plc (MDT) is the stronger overall head-to-head candidate over Stryker Corporation (SYK) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, R&D & Supply-Chain Moat). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas MDT carries 45.8/100 (HOLD) at $103.38 (17.0x Forward P/E, 20.1% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. MDT 45.8/100 HOLD), MDT captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (20.1% vs. 24.0% operating margin) and revenue trajectory (+13.7% vs. +7.6% YoY).
MDT leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with MDT at +13.7% YoY revenue growth and +40.7% YoY earnings growth on $37.5B TTM revenue (65.3% gross margin, 20.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SYK cumulative revenue shifted +68.8% while MDT shifted +19.0%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 45.2% of Rev ($17.0B) (0 disclosures) for MDT.
MDT screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas MDT trades at 17.0x Forward P/E, 24.8x Trailing P/E, 1.83x PEG, and 4.1x EV/Revenue (16.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus MDT (10.7% ROE) capital efficiency.
In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, MDT carries 30.6% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.15β · 33% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MDT vs SYK · Reverse Pair
SYK vs BDX
· Sector Peer
SYK vs TMO
· Sector Peer
SYK vs BSX
· Sector Peer
MDT vs ABT
· Sector Peer
MDT vs BSX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem